Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD161 Antibody Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 Market by Application
1.3.1 Global CD161 Antibody Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Immunochemistry (IHC)
1.3.3 Immunofluorescence (IF)
1.3.4 Immunoprecipitation (IP)
1.3.5 Western Blot (WB)
1.3.6 ELISA
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD161 Antibody Market Perspective (2018-2033)
2.2 CD161 Antibody Growth Trends by Region
2.2.1 Global CD161 Antibody Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 CD161 Antibody Historic Market Size by Region (2018-2023)
2.2.3 CD161 Antibody Forecasted Market Size by Region (2024-2033)
2.3 CD161 Antibody Market Dynamics
2.3.1 CD161 Antibody Industry Trends
2.3.2 CD161 Antibody Market Drivers
2.3.3 CD161 Antibody Market Challenges
2.3.4 CD161 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CD161 Antibody Players by Revenue
3.1.1 Global Top CD161 Antibody Players by Revenue (2018-2023)
3.1.2 Global CD161 Antibody Revenue Market Share by Players (2018-2023)
3.2 Global CD161 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CD161 Antibody Revenue
3.4 Global CD161 Antibody Market Concentration Ratio
3.4.1 Global CD161 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD161 Antibody Revenue in 2022
3.5 CD161 Antibody Key Players Head office and Area Served
3.6 Key Players CD161 Antibody Product Solution and Service
3.7 Date of Enter into CD161 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CD161 Antibody Breakdown Data by Type
4.1 Global CD161 Antibody Historic Market Size by Type (2018-2023)
4.2 Global CD161 Antibody Forecasted Market Size by Type (2024-2033)
5 CD161 Antibody Breakdown Data by Application
5.1 Global CD161 Antibody Historic Market Size by Application (2018-2023)
5.2 Global CD161 Antibody Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America CD161 Antibody Market Size (2018-2033)
6.2 North America CD161 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America CD161 Antibody Market Size by Country (2018-2023)
6.4 North America CD161 Antibody Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CD161 Antibody Market Size (2018-2033)
7.2 Europe CD161 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe CD161 Antibody Market Size by Country (2018-2023)
7.4 Europe CD161 Antibody Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CD161 Antibody Market Size (2018-2033)
8.2 Asia-Pacific CD161 Antibody Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific CD161 Antibody Market Size by Region (2018-2023)
8.4 Asia-Pacific CD161 Antibody Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CD161 Antibody Market Size (2018-2033)
9.2 Latin America CD161 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America CD161 Antibody Market Size by Country (2018-2023)
9.4 Latin America CD161 Antibody Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CD161 Antibody Market Size (2018-2033)
10.2 Middle East & Africa CD161 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa CD161 Antibody Market Size by Country (2018-2023)
10.4 Middle East & Africa CD161 Antibody Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BD Biosciences
11.1.1 BD Biosciences Company Detail
11.1.2 BD Biosciences Business Overview
11.1.3 BD Biosciences CD161 Antibody Introduction
11.1.4 BD Biosciences Revenue in CD161 Antibody Business (2018-2023)
11.1.5 BD Biosciences Recent Development
11.2 GeneTex
11.2.1 GeneTex Company Detail
11.2.2 GeneTex Business Overview
11.2.3 GeneTex CD161 Antibody Introduction
11.2.4 GeneTex Revenue in CD161 Antibody Business (2018-2023)
11.2.5 GeneTex Recent Development
11.3 RayBiotech
11.3.1 RayBiotech Company Detail
11.3.2 RayBiotech Business Overview
11.3.3 RayBiotech CD161 Antibody Introduction
11.3.4 RayBiotech Revenue in CD161 Antibody Business (2018-2023)
11.3.5 RayBiotech Recent Development
11.4 LifeSpan BioSciences
11.4.1 LifeSpan BioSciences Company Detail
11.4.2 LifeSpan BioSciences Business Overview
11.4.3 LifeSpan BioSciences CD161 Antibody Introduction
11.4.4 LifeSpan BioSciences Revenue in CD161 Antibody Business (2018-2023)
11.4.5 LifeSpan BioSciences Recent Development
11.5 BioLegend
11.5.1 BioLegend Company Detail
11.5.2 BioLegend Business Overview
11.5.3 BioLegend CD161 Antibody Introduction
11.5.4 BioLegend Revenue in CD161 Antibody Business (2018-2023)
11.5.5 BioLegend Recent Development
11.6 Abeomics
11.6.1 Abeomics Company Detail
11.6.2 Abeomics Business Overview
11.6.3 Abeomics CD161 Antibody Introduction
11.6.4 Abeomics Revenue in CD161 Antibody Business (2018-2023)
11.6.5 Abeomics Recent Development
11.7 Bioss
11.7.1 Bioss Company Detail
11.7.2 Bioss Business Overview
11.7.3 Bioss CD161 Antibody Introduction
11.7.4 Bioss Revenue in CD161 Antibody Business (2018-2023)
11.7.5 Bioss Recent Development
11.8 Novus Biologicals
11.8.1 Novus Biologicals Company Detail
11.8.2 Novus Biologicals Business Overview
11.8.3 Novus Biologicals CD161 Antibody Introduction
11.8.4 Novus Biologicals Revenue in CD161 Antibody Business (2018-2023)
11.8.5 Novus Biologicals Recent Development
11.9 Tonbo Biosciences
11.9.1 Tonbo Biosciences Company Detail
11.9.2 Tonbo Biosciences Business Overview
11.9.3 Tonbo Biosciences CD161 Antibody Introduction
11.9.4 Tonbo Biosciences Revenue in CD161 Antibody Business (2018-2023)
11.9.5 Tonbo Biosciences Recent Development
11.10 Bio-Rad
11.10.1 Bio-Rad Company Detail
11.10.2 Bio-Rad Business Overview
11.10.3 Bio-Rad CD161 Antibody Introduction
11.10.4 Bio-Rad Revenue in CD161 Antibody Business (2018-2023)
11.10.5 Bio-Rad Recent Development
11.11 Cell Sciences
11.11.1 Cell Sciences Company Detail
11.11.2 Cell Sciences Business Overview
11.11.3 Cell Sciences CD161 Antibody Introduction
11.11.4 Cell Sciences Revenue in CD161 Antibody Business (2018-2023)
11.11.5 Cell Sciences Recent Development
11.12 Miltenyi Biotec
11.12.1 Miltenyi Biotec Company Detail
11.12.2 Miltenyi Biotec Business Overview
11.12.3 Miltenyi Biotec CD161 Antibody Introduction
11.12.4 Miltenyi Biotec Revenue in CD161 Antibody Business (2018-2023)
11.12.5 Miltenyi Biotec Recent Development
11.13 R&D Systems
11.13.1 R&D Systems Company Detail
11.13.2 R&D Systems Business Overview
11.13.3 R&D Systems CD161 Antibody Introduction
11.13.4 R&D Systems Revenue in CD161 Antibody Business (2018-2023)
11.13.5 R&D Systems Recent Development
11.14 BMA Biomedicals
11.14.1 BMA Biomedicals Company Detail
11.14.2 BMA Biomedicals Business Overview
11.14.3 BMA Biomedicals CD161 Antibody Introduction
11.14.4 BMA Biomedicals Revenue in CD161 Antibody Business (2018-2023)
11.14.5 BMA Biomedicals Recent Development
11.15 AAT Bioquest
11.15.1 AAT Bioquest Company Detail
11.15.2 AAT Bioquest Business Overview
11.15.3 AAT Bioquest CD161 Antibody Introduction
11.15.4 AAT Bioquest Revenue in CD161 Antibody Business (2018-2023)
11.15.5 AAT Bioquest Recent Development
11.16 Biobyt
11.16.1 Biobyt Company Detail
11.16.2 Biobyt Business Overview
11.16.3 Biobyt CD161 Antibody Introduction
11.16.4 Biobyt Revenue in CD161 Antibody Business (2018-2023)
11.16.5 Biobyt Recent Development
11.17 Jingjie PTM BioLab
11.17.1 Jingjie PTM BioLab Company Detail
11.17.2 Jingjie PTM BioLab Business Overview
11.17.3 Jingjie PTM BioLab CD161 Antibody Introduction
11.17.4 Jingjie PTM BioLab Revenue in CD161 Antibody Business (2018-2023)
11.17.5 Jingjie PTM BioLab Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global CD161 Antibody Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Monoclonal
Table 3. Key Players of Polyclonal
Table 4. Global CD161 Antibody Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global CD161 Antibody Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global CD161 Antibody Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global CD161 Antibody Market Share by Region (2018-2023)
Table 8. Global CD161 Antibody Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global CD161 Antibody Market Share by Region (2024-2033)
Table 10. CD161 Antibody Market Trends
Table 11. CD161 Antibody Market Drivers
Table 12. CD161 Antibody Market Challenges
Table 13. CD161 Antibody Market Restraints
Table 14. Global CD161 Antibody Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global CD161 Antibody Market Share by Players (2018-2023)
Table 16. Global Top CD161 Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD161 Antibody as of 2022)
Table 17. Ranking of Global Top CD161 Antibody Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by CD161 Antibody Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players CD161 Antibody Product Solution and Service
Table 21. Date of Enter into CD161 Antibody Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global CD161 Antibody Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global CD161 Antibody Revenue Market Share by Type (2018-2023)
Table 25. Global CD161 Antibody Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global CD161 Antibody Revenue Market Share by Type (2024-2033)
Table 27. Global CD161 Antibody Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global CD161 Antibody Revenue Market Share by Application (2018-2023)
Table 29. Global CD161 Antibody Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global CD161 Antibody Revenue Market Share by Application (2024-2033)
Table 31. North America CD161 Antibody Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America CD161 Antibody Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America CD161 Antibody Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe CD161 Antibody Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe CD161 Antibody Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe CD161 Antibody Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific CD161 Antibody Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific CD161 Antibody Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific CD161 Antibody Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America CD161 Antibody Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America CD161 Antibody Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America CD161 Antibody Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa CD161 Antibody Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa CD161 Antibody Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa CD161 Antibody Market Size by Country (2024-2033) & (US$ Million)
Table 46. BD Biosciences Company Detail
Table 47. BD Biosciences Business Overview
Table 48. BD Biosciences CD161 Antibody Product
Table 49. BD Biosciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 50. BD Biosciences Recent Development
Table 51. GeneTex Company Detail
Table 52. GeneTex Business Overview
Table 53. GeneTex CD161 Antibody Product
Table 54. GeneTex Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 55. GeneTex Recent Development
Table 56. RayBiotech Company Detail
Table 57. RayBiotech Business Overview
Table 58. RayBiotech CD161 Antibody Product
Table 59. RayBiotech Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 60. RayBiotech Recent Development
Table 61. LifeSpan BioSciences Company Detail
Table 62. LifeSpan BioSciences Business Overview
Table 63. LifeSpan BioSciences CD161 Antibody Product
Table 64. LifeSpan BioSciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 65. LifeSpan BioSciences Recent Development
Table 66. BioLegend Company Detail
Table 67. BioLegend Business Overview
Table 68. BioLegend CD161 Antibody Product
Table 69. BioLegend Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 70. BioLegend Recent Development
Table 71. Abeomics Company Detail
Table 72. Abeomics Business Overview
Table 73. Abeomics CD161 Antibody Product
Table 74. Abeomics Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 75. Abeomics Recent Development
Table 76. Bioss Company Detail
Table 77. Bioss Business Overview
Table 78. Bioss CD161 Antibody Product
Table 79. Bioss Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 80. Bioss Recent Development
Table 81. Novus Biologicals Company Detail
Table 82. Novus Biologicals Business Overview
Table 83. Novus Biologicals CD161 Antibody Product
Table 84. Novus Biologicals Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 85. Novus Biologicals Recent Development
Table 86. Tonbo Biosciences Company Detail
Table 87. Tonbo Biosciences Business Overview
Table 88. Tonbo Biosciences CD161 Antibody Product
Table 89. Tonbo Biosciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 90. Tonbo Biosciences Recent Development
Table 91. Bio-Rad Company Detail
Table 92. Bio-Rad Business Overview
Table 93. Bio-Rad CD161 Antibody Product
Table 94. Bio-Rad Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 95. Bio-Rad Recent Development
Table 96. Cell Sciences Company Detail
Table 97. Cell Sciences Business Overview
Table 98. Cell Sciences CD161 Antibody Product
Table 99. Cell Sciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 100. Cell Sciences Recent Development
Table 101. Miltenyi Biotec Company Detail
Table 102. Miltenyi Biotec Business Overview
Table 103. Miltenyi Biotec CD161 Antibody Product
Table 104. Miltenyi Biotec Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 105. Miltenyi Biotec Recent Development
Table 106. R&D Systems Company Detail
Table 107. R&D Systems Business Overview
Table 108. R&D Systems CD161 Antibody Product
Table 109. R&D Systems Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 110. R&D Systems Recent Development
Table 111. BMA Biomedicals Company Detail
Table 112. BMA Biomedicals Business Overview
Table 113. BMA Biomedicals CD161 Antibody Product
Table 114. BMA Biomedicals Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 115. BMA Biomedicals Recent Development
Table 116. AAT Bioquest Company Detail
Table 117. AAT Bioquest Business Overview
Table 118. AAT Bioquest CD161 Antibody Product
Table 119. AAT Bioquest Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 120. AAT Bioquest Recent Development
Table 121. Biobyt Company Detail
Table 122. Biobyt Business Overview
Table 123. Biobyt CD161 Antibody Product
Table 124. Biobyt Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 125. Biobyt Recent Development
Table 126. Jingjie PTM BioLab Company Detail
Table 127. Jingjie PTM BioLab Business Overview
Table 128. Jingjie PTM BioLab CD161 Antibody Product
Table 129. Jingjie PTM BioLab Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 130. Jingjie PTM BioLab Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CD161 Antibody Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global CD161 Antibody Market Share by Type: 2022 VS 2033
Figure 3. Monoclonal Features
Figure 4. Polyclonal Features
Figure 5. Global CD161 Antibody Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global CD161 Antibody Market Share by Application: 2022 VS 2033
Figure 7. Immunochemistry (IHC) Case Studies
Figure 8. Immunofluorescence (IF) Case Studies
Figure 9. Immunoprecipitation (IP) Case Studies
Figure 10. Western Blot (WB) Case Studies
Figure 11. ELISA Case Studies
Figure 12. Others Case Studies
Figure 13. CD161 Antibody Report Years Considered
Figure 14. Global CD161 Antibody Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global CD161 Antibody Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global CD161 Antibody Market Share by Region: 2022 VS 2033
Figure 17. Global CD161 Antibody Market Share by Players in 2022
Figure 18. Global Top CD161 Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD161 Antibody as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by CD161 Antibody Revenue in 2022
Figure 20. North America CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America CD161 Antibody Market Share by Country (2018-2033)
Figure 22. United States CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe CD161 Antibody Market Share by Country (2018-2033)
Figure 26. Germany CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific CD161 Antibody Market Share by Region (2018-2033)
Figure 34. China CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America CD161 Antibody Market Share by Country (2018-2033)
Figure 42. Mexico CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa CD161 Antibody Market Share by Country (2018-2033)
Figure 46. Turkey CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. BD Biosciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 49. GeneTex Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 50. RayBiotech Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 51. LifeSpan BioSciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 52. BioLegend Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 53. Abeomics Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 54. Bioss Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 55. Novus Biologicals Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 56. Tonbo Biosciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 57. Bio-Rad Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 58. Cell Sciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 59. Miltenyi Biotec Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 60. R&D Systems Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 61. BMA Biomedicals Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 62. AAT Bioquest Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 63. Biobyt Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 64. Jingjie PTM BioLab Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed